|Table of Contents|

Observation on efficacy and adverse reactions of topotecan and irinotecan in treatment of elderly patients with small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 06
Page:
905-907
Research Field:
Publishing date:

Info

Title:
Observation on efficacy and adverse reactions of topotecan and irinotecan in treatment of elderly patients with small cell lung cancer
Author(s):
Nie Lei; Xue Yingli; Li Ya; Liu Min; Ding Haibin
Tumor Hospital of Shaanxi Province,Shaanxi Xi'an 710061,China.
Keywords:
topotecan; irinotecan; elderly patients with small cell lung cancer; efficacy; adverse reaction
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2017.06.017
Abstract:
Objective:To observe the clinical efficacy and adverse reaction of topotecan (TPT) alone and irinotecan (CPT-11) alone in treatment of elderly patients with small cell lung cancer (SCLC).Methods:50 elderly patients with SCLC (28 male and 22 female) from Tumor Hospital of Shaanxi Province were enrolled in this study from June 2013 to November 2015.Patients were randomly divided into TPT group and CPT-11 group.TPT and CPT-11 was given at 1.2mg/m2 at day 1 to day 5 and 65mg/m2 at day one and day 8 respectively by injection for three weeks as a chemotherapy cycle for 2 to 6 cycles.White blood cell amount,platelet amount,liver function,incidence of delayed diarrhea and anemia were collected during the follow-up lasting for 6 to 20 months.Results:There was no significant difference in efficacy such as the objective response rate,survival rate and survival time between topotecan and irinotecan (P＞0.05).However,TPT patients showed statistically more severe leukocytopenia than CPT-11 (64% vs 32%,P=0.048).The incidence of delayed diarrhea in CPT-11 group was significantly higher than that in TPT group (64% vs 20%,P=0.004).Conclusion:Topotecan and irinotecan are the same effective in elderly patients with small cell lung cancer.Topotecan causes severe bone marrow suppression while irinotecan often causes more often gastrointestinal adverse reaction and it should be concered during chemotherapy.

References:

［1］ Liu WS,Zhao LJ,Guan Y,et al.Relationship between the effect of induction chemotherapy and timing of radiotherapy in limited-disease small-cell lung cancer ［J］.Chin J Clin Oncol,2014,41(1):73-77.［刘维帅,赵路军,关勇,等.局限期小细胞肺癌诱导化疗疗效与放疗时机的关系探讨［J］.中国肿瘤临床,2014,41(1):73-77.］
［2］ Shaw AT,Kim DW,Mehra R,et al.Ceritinib in ALK-rearranged non-small-cell lung cancer［J］.New England J Med,2014,370(13):1189-1197.
［3］ Zhu YY,Ge W,Xv HL,et al.The effect of Paclitaxe combined with Cisplatin and Etoposide comparing with Cisplatin and Etoposide on patients with small cell lung cancer:a systematic review［J］.China Medical Herald,2014,11(13):62-66.［朱园园,戈伟,徐慧琳,等.紫杉醇联合顺铂/依托泊苷与顺铂/依托泊苷治疗小细胞肺癌的系统评价［J］.中国医药导报,2014,11(13):62-66.］
［4］ Borghaei H,Pazares L,Horn L，et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer［J］.New England J Med,2015,373(17):1627-1639.
［5］ Gong P,Liang WJ,Shi BG,et al.Analysis on survival status of inpatients with small cell lung cancer and influencing factors of prognosis ［J］.Pract Prev Med,2014,21(4):398-402.
［6］ Kang GQ,Xia YB,Zhao XS.Evaluation analysis of lung cancer with brain metastasis patients after stereotactic radiotherapy MRI change condition and for short-term effect［J］.Chin J CT and MRI,2015,13(5):48-51.［康国庆,夏玉兵,赵秀升.肺癌脑转移立体定向放疗后患者MRI变化情况及对近期疗效的评价分析［J］.中国CT和MRI杂志,2015,13(5):48-51.］
［7］ Liu D,Zhao YX,Bai L,et al.Analysis on the charateristics and gender differences of clinical pathological stage metastasis in 378 small cell lung cancer patients ［J］.Modern Oncology,2014,22(2):326-329.［刘丹,赵玉霞,白露,等.378例小细胞肺癌患者临床病理分期转移特征及性别差异［J］.现代肿瘤医学,2014,22(2):326-329.］
［8］ Liu ZY,Liu NB,Zhang BZ,et al.Relationship between the curative effect of chemoradiotherapy and brain metastasis in limited-disease small cell lung cancer ［J］.Chin J Clin Oncol,2015,8(15):756-759.［刘志艳,刘宁波,张宝忠,等.局限期小细胞肺癌放化疗后疗效与脑转移的关系探讨［J］.中国肿瘤临床,2015,8(15):756-759.］
［9］ Zhao H,Ai YQ,Zheng J,et al.Efficacy of chemoradio-therapy combined with cell immune in the treatment of extensive small cell lung cancer ［J］.China Med Herald,2016,13(2):104-108.［赵华,艾月琴,郑劼,等.广泛期小细胞肺癌放化疗联合细胞免疫治疗的效果［J］.中国医药导报,2016,13(2):104-108.］
［10］ Garon EB,Ciuleanu TE,Arrieta O,et al.Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL):a multicentre,double-blind,randomised phase3 trial［J］.Lancet,2014,384(9944):665-673.
［11］ Cai HP,Wang Z.Meta-analysis of effect and safety of standard regimens and weekly regimens of topotecan treating NSCLC［J］.J Pharmaceut Pract,2014,32(1):23-26.［蔡和平,王卓.拓扑替康标准方案与周疗方案治疗小细胞肺癌的荟萃分析［J］.药学实践杂志,2014,32(1):23-26.］
［12］ Chen JH,Li B,Zhao KG.The clinical effect of paclitaxel combined with topotecan in the treatment in refractory or relapsed small cell lung cancer ［J］.For All Health,2016,10(2):114-115.［陈敬华,李宾,赵凯歌.白蛋白紫杉醇联合拓扑替康治疗复发难治小细胞肺癌的临床效果［J］.大家健康学术版,2016,10(2):114-115.］
［13］ Garon EB,Rizvi NA,Hui R,et al.Pembrolizumab for the treatment of non-small-cell lung cancer［J］.New England J Med,2015,372(21):179-188.
［14］ Rizvi NA,Hellmann MD,Snyder A,et al.Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer［J］.Science,2015,348(6230):124-128.

Memo

Memo:
-
Last Update: 2017-01-26